It was recently made public in a press release dated November 9, 2022, that Saudi Arabian medical laboratory companies Al Farabi Medical Labs and Dante Labs have formed a union that will empower Saudi Arabian citizens to access their genome profiles.
Al Farabi Medical Laboratories, one of the top medical labor companies in the entire Kingdom of Saudi Arabia, has more than 50 locations throughout the Kingdom, serving all residents of Saudi Arabia. Now, with this new partnership agreement with Dante Labs, it will be able to add to its services by providing genome testing. Dante Labs is a world leader in genomics and precision medicine. The range of genomic tests will include, but are not limited to, Whole Genome Sequencing and Whole Exome Sequencing with interpretation and Non-Invasive Prenatal Testing (NIPT).
Each leader of the two companies made statements regarding the new union. The CEO and co-founder of Dante Labs, Andrea Riposati, expressed Dante Labs’ excitement about providing cutting-edge genetic testing services in collaboration with Al Farabi Medical Labs in the Kingdom of Saudi Arabia. “We look forward to assisting Al Farabi Medical Labs in growing and realizing its forward-thinking mission. Together, we want to make it possible for Saudi Arabian people to get customized and improved healthcare based on whole genome sequencing.”
Al Farabi Medical Laboratories’ founder and general manager, Dr. Mohamed Marie, stated, “We are proud to partner with Dante Labs and to have the ability to leverage their technology and knowledge in the Kingdom of Saudi Arabia. Our partner in genetic analysis and other genomic products will be Dante Labs. As with all other aspects of healthcare, our goal is to provide our patients with the best services possible. We believe this new union with Dante Labs will serve our mission to provide the most comprehensive set of tests for citizens of the Kingdom of Saudi Arabia.
Learn More About Dante Labs
A worldwide genomic information company, Dante Labs, is developing and commercializing a new class of revolutionary longevity and health applications based on whole genome sequencing and artificial intelligence. The company strives to deliver better patient outcomes, preventive, improved diagnostics, and individualized treatment using its platform. Among the company’s assets are one of the leading private genome databases with permission for study, proprietary software created to unleash the potential of genomic data at scale, and unique technologies that allow an enterprise approach to genomic sequencing.
Learn More About Al Farabi Medical Labs
Since the beginning, Al Farabi Medical Laboratories has adopted and continues to pursue the strategy of attracting and localizing the latest technologies in various diagnostic procedures to work on challenging medical issues in terms of performance quality and turnaround time. In doing so, and to comply with local and international standards and requirements for laboratory quality and workplace safety, Al Farabi Medical Labs has adopted stringent working procedures. Consequently, the company has earned CBAHI and JCI, two national and international accreditations.